Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NPI 2358 × Thoracic × Clear all

Phase

Phase 1/2 3 Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 246 Cisplatin 196 Pemetrexed 166 Paclitaxel 127 Docetaxel 115 pembrolizumab 92 Gemcitabine 75 Etoposide 57 Erlotinib Hydrochloride 54 Radiotherapy 49 durvalumab 44 Bevacizumab 39 Vinorelbine 38 atezolizumab 36 Gefitinib 36 Nivolumab 35 Drug Therapy 30 osimertinib 25 Topotecan 23 tislelizumab 19 130-nm albumin-bound paclitaxel 19 Radiosurgery 18 Ipilimumab 15 Crizotinib 15 Albumin-Bound Paclitaxel 13 aumolertinib 12 Platinum 12 Magnetic Resonance Spectroscopy 12 Dexamethasone 12 Cyclophosphamide 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02504489 2022-09-10

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡